Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Conatus Pharmaceutic (CNAT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,631
  • Shares Outstanding, K 33,165
  • Annual Sales, $ 33,590 K
  • Annual Income, $ -18,010 K
  • 60-Month Beta 3.11
  • Price/Sales 0.79
  • Price/Cash Flow N/A
  • Price/Book 1.13
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.57
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/01/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.10
  • Number of Estimates 3
  • High Estimate 0.00
  • Low Estimate -0.17
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.72 +15.97%
on 04/26/19
0.97 -13.92%
on 05/06/19
+0.02 (+3.09%)
since 04/24/19
3-Month
0.69 +21.63%
on 04/17/19
3.08 -72.89%
on 03/21/19
-1.05 (-55.59%)
since 02/22/19
52-Week
0.69 +21.63%
on 04/17/19
6.74 -87.60%
on 09/24/18
-2.84 (-77.25%)
since 05/24/18

Most Recent Stories

More News
Conatus' (CNAT) Earnings, Revenues Miss Estimates in Q1

Conatus, (CNAT) earnings and revenues lag estimates in the first-quarter of 2019. Emricasan remains in focus.

CNAT : 0.83 (+3.99%)
PDLI : 2.96 (-0.67%)
NVS : 87.52 (+3.65%)
PFE : 41.95 (+0.07%)
Conatus Pharmaceuticals (CNAT) Reports Q1 Loss, Lags Revenue Estimates

Conatus (CNAT) delivered earnings and revenue surprises of -16.67% and -15.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

CNAT : 0.83 (+3.99%)
Conatus: 1Q Earnings Snapshot

SAN DIEGO (AP) _ Conatus Pharmaceuticals Inc. (CNAT) on Thursday reported a loss of $4.7 million in its first quarter.

CNAT : 0.83 (+3.99%)
Conatus Pharmaceuticals Reports First Quarter 2019 Financial Results and Program Updates

Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the first quarter ended March 31, 2019, and provided updates on its development programs.

CNAT : 0.83 (+3.99%)
Conatus Pharmaceuticals Announces Publication Demonstrating that Emricasan Ameliorates Portal Hypertension, Improves Liver Structure and Function in a Preclinical Model of Advanced Cirrhosis

Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced a new publication in Hepatology Communications detailing results following seven-day treatment with emricasan, the company's first-in-class pan-caspase...

CNAT : 0.83 (+3.99%)
Conatus Pharmaceuticals Announces Publication Demonstrating that Emricasan Ameliorates Portal Hypertension, Improves Liver Structure and Function in a Preclinical Model of Advanced Cirrhosis

Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced a new publication in Hepatology Communications detailing results following seven-day treatment with emricasan, the company's first-in-class pan-caspase...

CNAT : 0.83 (+3.99%)
New Research: Key Drivers of Growth for Conatus Pharmaceuticals, MasTec, Cyclacel Pharmaceuticals, Melinta Therapeutics, North American Construction Group, and B.O.S. Better Online Solutions -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Conatus Pharmaceuticals Inc....

CNAT : 0.83 (+3.99%)
MLNT : 2.64 (-6.05%)
NOA : 11.23 (+0.54%)
MTZ : 46.05 (+0.66%)
BOSC : 2.80 (-3.78%)
CYCC : 0.76 (+22.26%)
Conatus Late-breaker Oral Presentation at EASL Meeting Details Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension

Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today that the company's late-breaker oral presentation at The International Liver Congress(TM) 2019, the Annual Meeting of the European Association...

CNAT : 0.83 (+3.99%)
Why Is Conatus (CNAT) Down 37.8% Since Last Earnings Report?

Conatus (CNAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CNAT : 0.83 (+3.99%)
Conatus Pharmaceuticals to Participate in H.C. Wainwright Global Life Sciences Conference

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has accepted an invitation to participate in the H.C. Wainwright Global Life Sciences Conference (April 7-9 in London). Conatus senior management will conduct...

CNAT : 0.83 (+3.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade CNAT with:

Business Summary

Conatus Pharmaceuticals, Inc. is a biotechnology company. It is focused on developing and commercializing medicines to treat liver disease. The Company is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of...

See More

Key Turning Points

2nd Resistance Point 0.87
1st Resistance Point 0.85
Last Price 0.83
1st Support Level 0.81
2nd Support Level 0.79

See More

52-Week High 6.74
Fibonacci 61.8% 4.42
Fibonacci 50% 3.71
Fibonacci 38.2% 3.00
Last Price 0.83
52-Week Low 0.69

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar